INTRODUCTION Venom allergy, though rare, may seriously influence health-related quality of life (HRQoL). There is a paucity of research on HRQoL of adolescents and young adults with Hymenoptera venom allergy. The aim was to assess the level of HRQoL and to evaluate its independent predictors in Polish adolescents and young adults treated with venom immunotherapy. MATERIAL AND METHODS A multic...

BACKGROUND Allergen immunotherapy (AIT) is currently the only immune-modifying treatment for allergic disease. The clinical efficacy of AIT for the treatment of allergic rhinitis and bronchial asthma is well documented. However, many factors including inconvenience, cost, side effects, and adherence influence the initiation and persistence of AIT, and patients lack knowledge and have misconcept...

results we performed rush on 77 patients. kappa index was 0.71 (p value = 0.000), reflecting acceptable general agreement between initial impression and final diagnosis. for hypovolemic, cardiogenic and obstructive shock, the protocol had an npv above 97% yet it had a lower ppv. for shock with distributive or mixed etiology, rush showed a ppv of 100% but it had low sensitivity. subgroup analysi...

Bee venom phospholipase A2 (PLA) is the major allergen in bee sting allergy. It displays three peptide and a glycopeptide T cell epitopes, which are recognized by both allergic and non-allergic bee venom sensitized subjects. In this study PLA- and PLA epitope-specific T cell and cytokine responses in PBMC of bee sting allergic patients were investigated before and after 2 mo of rush immunothera...